Abstract Body

The interferon-induced transmembrane (IFITM) proteins are known for inhibiting the entry of a wide array of viruses into host cells. Furthermore, when IFITM3 is present in virus-producing cells, it reduces the fusion potential of HIV-1 virions, but the mechanism is poorly understood. 

To describe the antiviral mechanism of IFITM3 and to discover modes of viral evasion, we took advantage of a murine leukemia virus (MLV)-based pseudotyping system. By controlling IFITM3 and envelope (Env) levels in virus-producing cells, we found that IFITM3 potently inhibits MLV infectivity when Env levels are limiting. 

Loss of infectivity was associated with defective proteolytic processing of Env and lysosomal degradation of the Env precursor. Ecotropic and xenotropic variants of MLV Env, as well as HIV-1 Env and vesicular stomatitis virus glycoprotein (VSV-G), are sensitive to IFITM3, whereas Ebola glycoprotein is resistant, suggesting that IFITM3 selectively inactivates certain viral glycoproteins. Furthermore, endogenous IFITM3 in human and murine cells negatively regulates MLV Env abundance. However, the negative impact of IFITM3 on virion infectivity is greater than its impact on Env incorporation into virions, suggesting that IFITM3 also impairs Env function. Finally, we demonstrate that the presence of glycosylated Gag (glycoGag), the only accessory protein encoded by MLV, confers resistance to the IFITM-mediated loss of infectivity. GlycoGag has previously been shown to counteract another antiviral transmembrane proteins known as SERINC. Importantly, glycoGag rescues virus infectivity in the presence of IFITM3 without enhancing Env incorporation, indicating that glycoGag counteracts the cryptic function of IFITM3 which acts on Env function. This represents the first description of a viral auxiliary protein displaying the capacity to antagonize or enable viral evasion of IFITM3.

Overall, we demonstrate that IFITM3: (i) impairs virion infectivity by decreasing Env quantity and Env function, (ii) glycoGag confers virions with resistance to IFITM3 and, (iii) the antiviral activities of IFITM3 and SERINC3/5 may be linked. We are now testing whether the antiviral function of IFITM3 is maintained in SERINC5 knockout cells and whether other retroviral accessory proteins, such as HIV-1 Nef and EIAV S2, also exhibit the capacity to counteract IFITM3.